 |
|
 |
| |
| |
To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download. |
| |
|
|
| |
|
|
 |
Roundtable Discussion: Charles E Geyer Jr, MD and John Mackey, MD
Charles E Geyer Jr, MD
Director of Medical Affairs
National Surgical Adjuvant Breast and Bowel Project
Vice-Chair, Department of Human Oncology
Allegheny General Hospital
Pittsburgh, Pennsylvania
John Mackey, MD
Medical Oncologist, Cross Cancer Institute
Professor, Medical and Experimental Oncology, University of Alberta
Chair of Research, Northern Alberta Breast Cancer Program
Executive Director, Cancer International Research Group
Edmonton, Canada |
|
| |
Click here to download the entire discussion |
|
|
| Track 1 |
Long-term risk of recurrence in hormone receptor-positive breast cancer and the implications of
continued endocrine therapy beyond five years |
 |
| Track 2 |
Bone density and prolonged use of aromatase inhibitors |
|
| Track 3 |
Duration of endocrine therapy in the clinical setting |
|
| Track 4 |
Theoretical concerns with long-term endocrine therapy |
|
| Track 5 |
Rationale for the BETH trial: An adjuvant study of chemotherapy/trastuzumab with or without
bevacizumab in HER2-positive breast cancer |
|
| Track 6 |
Mechanism of action and clinical benefit of bevacizumab combined with trastuzumab |
|
| Track 7 |
ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) study |
|
| Track 8 |
Safety of trastuzumab versus lapatinib |
|
| Track 9 |
Role of the Oncotype DX assay in the TAILORx study |
|
| Track 10 |
Challenge of enrolling patients on randomized clinical trials |
|
| Track 11 |
Use of the Oncotype DX assay in the clinical setting |
|
|
|
